Keyphrases
Body Mass Index
100%
Disease Outcome
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Serum Testosterone
100%
Castration-resistant
100%
Testosterone
66%
Prostate-specific Antigen
66%
Obesity
50%
Overall Survival
33%
Prednisone
33%
Obese Men
33%
Alkaline Phosphatase Level
33%
Clinically Significant
16%
Multivariate Analysis
16%
Hemoglobin
16%
Young Age
16%
Gleason Sum
16%
Clinical Trials
16%
Docetaxel
16%
Performance Status
16%
High Performance
16%
Mitoxantrone
16%
Current Therapies
16%
Morbid Obesity
16%
Hemodilution
16%
Randomized Phase III Trial
16%
Prostate Cancer Outcomes
16%
Median Body
16%
Index Level
16%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Prostate Cancer
100%
Prostate Specific Antigen
80%
Overall Survival
40%
Prednisone
40%
Alkaline Phosphatase
40%
Clinical Trial
20%
Epileptic Absence
20%
Gleason Score
20%
Docetaxel
20%
Mitoxantrone
20%
Biochemistry, Genetics and Molecular Biology
Body Mass
100%
Testosterone Blood Level
100%
Prostate-Specific Antigen
66%
Overall Survival
33%
Alkaline Phosphatase
33%
Prednisone
33%
Multivariate Analysis
16%
Clinical Trial
16%
Gleason Score
16%
Nursing and Health Professions